745 related articles for article (PubMed ID: 26581749)
1. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
2. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
3. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
7. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
8. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Game F
Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
Scheen AJ
Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
[TBL] [Abstract][Full Text] [Related]
11. Metformin and other antidiabetic agents in renal failure patients.
Lalau JD; Arnouts P; Sharif A; De Broe ME
Kidney Int; 2015 Feb; 87(2):308-22. PubMed ID: 24599253
[TBL] [Abstract][Full Text] [Related]
12. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
13. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
Hahr AJ; Molitch ME
Am J Kidney Dis; 2022 May; 79(5):728-736. PubMed ID: 34600745
[TBL] [Abstract][Full Text] [Related]
14. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.
Reilly JB; Berns JS
Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Abe M; Okada K; Soma M
Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
17. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Min T; Davies GI; Rice S; Chess J; Stephens JW
Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
[TBL] [Abstract][Full Text] [Related]
18. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
Siriyotha S; Lukkunaprasit T; Looareesuwan P; Nimitphong H; McKay GJ; Attia J; Thakkinstian A
Cardiovasc Diabetol; 2022 Nov; 21(1):248. PubMed ID: 36397062
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
